SCRIP ASKS…What Does 2021 Hold For Biopharma?
A broad survey of the industry’s expectations for the year to come.
Every December, Scrip asks industry leaders and experts to share their expectations for the year to come. With responses from more than 200 professionals, Scrip Asks…What Does 2021 Hold For Biopharma? provides an unprecedented insight into the biopharma universe’s collective crystal ball.
The full list of installments:
The biopharma industry has high ambitions to improve therapies for patients across many disease categories, drawing on a wealth of technological advances that have been emerging and maturing in recent years. Even after the mass mobilization against COVID-19, it is clear from the responses of the executives we surveyed that the sector has retained significant firepower to deploy across the disease spectrum.
“There continues to be a very exciting pipeline of innovations, launches coming up, and new disease areas that we can...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
